Current Oncology Reports

, Volume 5, Issue 2, pp 152–157 | Cite as

Chemoprevention of head and neck cancer

  • Katrina Y. Glover
  • Vali A. Papadimitrakopoulou
Article

Abstract

Squamous cell carcinoma of the head and neck is the most common epithelial neoplasm of the upper aerodigestive tract and represents a major health concern in the United States and worldwide. Invasive squamous cell carcinoma is the end result of a multiyear, multistep process of accumulation of genetic and phenotypic damage. Chemoprevention is defined as the use of pharmacologic or natural agents that inhibit the development of invasive cancer whether by blocking the DNA damage that initiates carcinogenesis or by arresting or reversing the progression of premalignant cells in which such damage has already occurred. Chemoprevention is widely recognized as an important area of research in head and neck cancer. This article reviews the field of chemoprevention and recent advances in molecular epidemiology and genetics. Current clinical trials are described.

Keywords

Epidermal Growth Factor Receptor Neck Cancer Aerodigestive Tract Premalignant Lesion Etretinate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Mashberg A: Re: Oral cavity cancer in non-users of tobacco. J Natl Cancer Inst 1993, 85:1525.PubMedCrossRefGoogle Scholar
  3. 3.
    Vokes EE, Weichselbaum RR, Lippman SM, et al.: Head and neck cancer. N Engl J Med 1993, 328:184–194.PubMedCrossRefGoogle Scholar
  4. 4.
    Cooper JS, Pajak TF, Rubin P, et al.: Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989. 17:449–456.PubMedGoogle Scholar
  5. 5.
    Lippman SM, Spitz M, Trizna Z, et al.: Epidemiology, biology, and chemoprevention of aerodigestive cancer. Cancer 1994, 74(Suppl):2719–2725.PubMedCrossRefGoogle Scholar
  6. 6.
    Jones AS, Morar P, Phillips DE, et al.: Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995, 75:1343–1353.PubMedCrossRefGoogle Scholar
  7. 7.
    Lippman SM, Hong WK: Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989, 17:691–694.PubMedGoogle Scholar
  8. 8.
    Sporn MB, Dunlop NM, Newton, DL, Smith JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976, 35:1332–1338.PubMedGoogle Scholar
  9. 9.
    Hong WK, Sporn MB: Recent advances in chemoprevention of cancer. Science 1997, 278:1073–1077.PubMedCrossRefGoogle Scholar
  10. 10.
    Rothman KJ, Cann CI, Flanders D, Fried MP: Epidemiology of laryngeal cancer. Epidemiol Rev 1980, 2:195–209.PubMedGoogle Scholar
  11. 11.
    Tuyns AJ, Esteve J, Raymond C: Cancer of the larynx/ hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer 1988, 41:483–491.PubMedCrossRefGoogle Scholar
  12. 12.
    De Stefani E, Correa P, Oreggia F, et al.: Risk factors for laryngeal cancer. Cancer 1987, 60:3087–3091.PubMedCrossRefGoogle Scholar
  13. 13.
    Saracci R: The interactions of tobacco smoking and other agents in cancer etiology. Epidemiol Rev 1987, 9:175–193.PubMedGoogle Scholar
  14. 14.
    Shields PG, Harris CC: Molecular epidemiology and the genetics of environmental cancer. JAMA 1991, 266:681–687.PubMedCrossRefGoogle Scholar
  15. 15.
    Hsu TC, Cherry LM, Samaan NA: Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet Cytogenet 1985, 17:307–313.PubMedCrossRefGoogle Scholar
  16. 16.
    Spitz MR, Fueger JJ, Beddingfield NA, et al.: Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res 1989, 49:4626–4628.PubMedGoogle Scholar
  17. 17.
    Spitz MR, Hogue A, Trizna Z, et al.: Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol Biomark Prev 1993, 2:329–333.Google Scholar
  18. 18.
    Knudson AG Jr, Hethcote HW, Brown BW: Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 1975, 72:5116–5120.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee JS, Kim S, Hong WK, et al.: Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 1993, 85:1951–1954.PubMedCrossRefGoogle Scholar
  20. 20.
    Voravud N, Shin DM, KO JY, et al.: Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis. Cancer Res 1993, 53:2874–2883.PubMedGoogle Scholar
  21. 21.
    Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J Med 2001, 345:1890–1900. A review of head and neck cancer highlighting new developments in the treatment of patients with locally advanced disease and molecular genetic changes that are likely to result in novel diagnostic and therapeutic options.PubMedCrossRefGoogle Scholar
  22. 22.
    Brennan JA, Boyle JO, Koch WM, et al.: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995, 332:712–717.PubMedCrossRefGoogle Scholar
  23. 23.
    Grandis R, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993, 53:3579–3584.PubMedGoogle Scholar
  24. 24.
    Grandis JR, Tweardy DJ, Melhem MF: Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998, 4:13–20.Google Scholar
  25. 25.
    Shin DM Ro JY, Hong WK, Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994, 54:3153–3159.PubMedGoogle Scholar
  26. 26.
    Mao L, Lee JS, Fan YH, et al.: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996, 2:682–685.PubMedCrossRefGoogle Scholar
  27. 27.
    Partridge M, Pateromichelaki SS, Phillips E, et al.: A casecontrol study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000, 60:3893–3898.PubMedGoogle Scholar
  28. 28.
    Rosin MP, Cheng X, Poh C, et al.: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000, 6:357–362.PubMedGoogle Scholar
  29. 29.
    van der Riet P, Nawroz H, Hruban RH, et al.: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994, 54:1156–1158.PubMedGoogle Scholar
  30. 30.
    Califano J, Westra WH, Meininger G, et al.: Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 2000, 6:347–352.PubMedGoogle Scholar
  31. 31.
    Guo Z, Yamaguchi K, Sanchez-Cespedes M, et al.: Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res 2001, 7:1963–1968.PubMedGoogle Scholar
  32. 32.
    Sanchez-Cespedes M, Esteller M, Wu L, et al.: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000, 60:892–895.PubMedGoogle Scholar
  33. 33.
    Hong WK, Endicott J, Itri LM, et al.: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986, 315:1501–1505.PubMedCrossRefGoogle Scholar
  34. 34.
    Lippman SM, Batsakis JG, Toth BB, et al.: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993, 328:15–20.PubMedCrossRefGoogle Scholar
  35. 35.
    Stich HF, Hornby AP, Mathew B, et al.: Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988, 40:93–101.PubMedCrossRefGoogle Scholar
  36. 36.
    Han J, Jiao L, Lu Y, et al.: Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 1990, 4:153–160.PubMedGoogle Scholar
  37. 37.
    Chiesa F, Tradati N, Merazza M, et al.: Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem 1993, 17F (Suppl):255–261.CrossRefGoogle Scholar
  38. 38.
    Agarwal R, Mukhdtar H: Cancer chemoprevention by polyphenols in green tea and artichoke. Adv Exp Med Biol 1996, 401:35–50.PubMedGoogle Scholar
  39. 39.
    Schantz SP, Ostroff JS: Novel approaches to the prevention of head and neck cancer. Proc Soc Exp Biol Med 1997, 216:275–282.PubMedGoogle Scholar
  40. 40.
    Blot WJ, Chow WH, McLaughlin JK: Tea and cancer: a review of the epidemiological evidence. Eur J Cancer Prev 1996, 5:425–438.PubMedGoogle Scholar
  41. 41.
    Yang CS, Wang ZY: Tea and cancer. J Natl Cancer Inst 1993, 85:1038–1049.PubMedCrossRefGoogle Scholar
  42. 42.
    Stich HF: Teas and tea components as inhibitors of carcinogen formation in model systems and man. Prev Med 1992, 21:377–384.PubMedCrossRefGoogle Scholar
  43. 43.
    Panje WR: Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981, 107:658–663.PubMedGoogle Scholar
  44. 44.
    Chan G, Boyle JO, Yang EK, et al.: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999, 59:991–994.PubMedGoogle Scholar
  45. 45.
    Messina M, Barnes S: The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991, 83:541–546.PubMedCrossRefGoogle Scholar
  46. 46.
    Messina MJ, Persky V, Setchell KD, Barnes S: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994, 21:113–131.PubMedCrossRefGoogle Scholar
  47. 47.
    Kennedy AR: Chemopreventive agents: protease inhibitors. Pharmacol Ther 1998, 78:167–209.PubMedCrossRefGoogle Scholar
  48. 48.
    Fournier DB, Erdman JW, Gordon GB: Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomark Prev 1998, 7:1055–1065.Google Scholar
  49. 49.
    Kennedy AR, Manzone H: Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. J Cell Biochem 1995, 22 (Suppl):188–194.CrossRefGoogle Scholar
  50. 50.
    Armstrong WB, Kennedy AR, Wan XS, et al.: Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomark Prev 2000, 9:43–47.Google Scholar
  51. 51.
    Papadimitrakopoulou VA, Clayman GL, Shin DM, et al.: Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999, 125:1083–1089.PubMedGoogle Scholar
  52. 52.
    Shin DM, Khuri FR, Murphy B: Combined interferon-alfa, 13-cisretinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001, 19:3010–3017. Retinoids and interferon have synergistic effects on lesions of the head and neck. Alpha-tocopherol is an agent with chemopreventive activity that is also known to reduce the toxicity of 13-cis retinoic acid. This study evaluates the combination of α-tocopherol, interferon alfa, and 13-cis retinoic acid in patients with locally advanced disease for prevention of recurrence or SPTs.PubMedGoogle Scholar
  53. 53.
    Hong WK, Lippman SM, Itri LM, et al.: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990, 323:795–801.PubMedCrossRefGoogle Scholar
  54. 54.
    Bolla M, Lefur R, Ton Van J, et al.: Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx: results of a multicentric doubleblind randomised study. Eur J Cancer 1994, 30A:767–772.PubMedCrossRefGoogle Scholar
  55. 55.
    Khuri FR, Kim ES, Lee JJ, et al.: The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomark Prev 2001, 10:823–829. The first large-scale chemoprevention study evaluating smoking status and its impact on second primary tumor development and recurrence rate in SCCHN. The results show higher SPT rates in active smokers versus „never” smokers and a significantly higher smoking-related SPT rate in active smokers compared with those who have never smoked.Google Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Katrina Y. Glover
  • Vali A. Papadimitrakopoulou
    • 1
  1. 1.Department of Thoracic/Head and Neck Medical OncologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations